-
Bayesian Benefit Risk Analysis
Authors:
Konstantinos Vamvourellis,
Konstantinos Kalogeropoulos,
Lawrence Phillips
Abstract:
The process of approving and assessing new drugs is often quite complicated, mainly due to the fact that multiple criteria need to be considered. A standard way to proceed is with benefit risk analysis, often under the Bayesian paradigm to account for uncertainty and combine data with expert judgement, which is operationalised via multi-criteria decision analysis (MCDA) scores. The procedure is ba…
▽ More
The process of approving and assessing new drugs is often quite complicated, mainly due to the fact that multiple criteria need to be considered. A standard way to proceed is with benefit risk analysis, often under the Bayesian paradigm to account for uncertainty and combine data with expert judgement, which is operationalised via multi-criteria decision analysis (MCDA) scores. The procedure is based on a suitable model to accommodate key features of the data, which are typically of mixed type and potentially depended, with factor models providing a standard choice. The contribution of this paper is threefold: first, we extend the family of existing structured factor models. Second, we provide a framework for choosing between them, which combines fit and out-of-sample predictive performance. Third, we present a sequential estimation framework that can offer multiple benefits: (i) it allows us to efficiently re-estimate MCDA scores of different drugs each time new data become available, thus getting an idea on potential fluctuations in differences between them, (ii) it can provide information on potential early stopping in cases of evident conclusions, thus reducing unnecessary further exposure to undesirable treatments; (iii) it can potentially allow to assign treatment groups dynamically based on research objectives. A drawback of sequential estimation is the increased computational time, but this can be mitigated by efficient sequential Monte Carlo schemes which we tailor in this paper to the context of Bayesian benefit risk analysis. The developed methodology is illustrated on real data on Type II diabetes patients who were administered Metformin (MET), Rosiglitazone (RSG) and a combination of the two (AVM).
△ Less
Submitted 29 April, 2022;
originally announced May 2022.
-
Sequential Bayesian Inference for Factor Analysis
Authors:
Konstantinos Vamvourellis,
Konstantinos Kalogeropoulos,
Irini Moustaki
Abstract:
We develop an efficient Bayesian sequential inference framework for factor analysis models observed via various data types, such as continuous, binary and ordinal data. In the continuous data case, where it is possible to marginalise over the latent factors, the proposed methodology tailors the Iterated Batch Importance Sampling (IBIS) of Chopin (2002) to handle such models and we incorporate Hami…
▽ More
We develop an efficient Bayesian sequential inference framework for factor analysis models observed via various data types, such as continuous, binary and ordinal data. In the continuous data case, where it is possible to marginalise over the latent factors, the proposed methodology tailors the Iterated Batch Importance Sampling (IBIS) of Chopin (2002) to handle such models and we incorporate Hamiltonian Markov Chain Monte Carlo. For binary and ordinal data, we develop an efficient IBIS scheme to handle the parameter and latent factors, combining with Laplace or Variational Bayes approximations. The methodology can be used in the context of sequential hypothesis testing via Bayes factors, which are known to have advantages over traditional null hypothesis testing. Moreover, the developed sequential framework offers multiple benefits even in non-sequential cases, by providing posterior distribution, model evidence and scoring rules (under the prequential framework) in one go, and by offering a more robust alternative computational scheme to Markov Chain Monte Carlo that can be useful in problematic target distributions.
△ Less
Submitted 26 January, 2022;
originally announced January 2022.
-
Model Assessment for a Generalised Bayesian Structural Equation Model
Authors:
Konstantinos Vamvourellis,
Konstantinos Kalogeropoulos,
Irini Moustaki
Abstract:
The paper proposes a novel model assessment paradigm aiming to address shortcoming of posterior predictive $p-$values, which provide the default metric of fit for Bayesian structural equation modelling (BSEM). The model framework of the paper focuses on the approximate zero approach, according to which parameters that would before set to zero (e.g. factor loadings) are now formulated to be approxi…
▽ More
The paper proposes a novel model assessment paradigm aiming to address shortcoming of posterior predictive $p-$values, which provide the default metric of fit for Bayesian structural equation modelling (BSEM). The model framework of the paper focuses on the approximate zero approach, according to which parameters that would before set to zero (e.g. factor loadings) are now formulated to be approximate zero via informative priors (Muthen and Asparouhov, 2012). The introduced model assessment procedure monitors the out-of-sample predictive performance of the fitted model, and together with a list of guidelines we provide, one can investigate whether the hypothesised model is supported by the data. We incorporate scoring rules and cross-validation to supplement existing model assessment metrics for Bayesian SEM. The proposed tools can be applied to models for both categorical and continuous data. The modelling of categorical and non-normally distributed continuous data is facilitated with the introduction of an item-individual random effect that can also be used for outlier detection. We study the performance of the proposed methodology via simulations. The factor model for continuous and binary data is fitted to data on the `Big-5' personality scale and the Fagerstrom test for nicotine dependence respectively.
△ Less
Submitted 28 June, 2022; v1 submitted 4 April, 2021;
originally announced April 2021.
